Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 543828 | NSE Symbol : | ISIN : INE00TV01023 | Industry : Trading |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
31-Jan-2025	30-Jan-2025	Preferential Issue	In continuation of the outcome of Board Meeting held on 10-Jan-2025, Fund Raising Committee of the Board at its meeting held on 30-Jan-2025 approved, inter alia, revision in list of allottees and change in Notice of EGM and issue of Corrigendum to the Notice of Extraordinary General Meeting scheduled on Tuesday, 04-Feb-2025.
06-Jan-2025	10-Jan-2025	Issue of Warrants	Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/01/2025 inter alia to consider and approve In terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended from time to time we hereby inform you that the meeting of the Board of Directors of Sudarshan Pharma Industries Limited (the Company) is scheduled to be held on Friday January 10 2025 inter-alia to transact following businesses: i. To evaluate the proposal for raising of funds to augment the financial resources of the Company by way of issue of securities convertible instruments through any permissible method as may be decided by the Board subject to such regulatory / statutory approvals as may be required including the approval of shareholders of the Company and to appoint necessary intermediaries if any for this purpose; and ii. any other matter with the permission of the Chairman. Raising of funds by way of creating, issuing and allotting up to 4,30,00,000 (Four Crores Thirty Lakhs Only) Fully Convertible Warrants Convertible into equivalent number of fully paid-up equity shares of the Company having face value of Re.1/- (Rupee One Only), in one or more tranches, to the persons belonging to 'Promoter / Promoter Group and 'Non-Promoter, Public Category' (As Per BSE Announcement dated on 10.01.2025)
18-Dec-2024	18-Dec-2024	Preferential Issue	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and pursuant to the approval of the members obtained at the Extra-ordinary General Meeting held on 30th September, 2024 by means of Special Resolution and approval of the members obtained by way of Postal Ballot dated 3rd November, 2024 by means of ordinary resolution and 'In-Principal Approval' obtained from BSE Limited, the Board of Directors of the Company have, at its meeting held on 18th December, 2024 at 3.00 p.m. and concluded at 6.15 p.m., has inter-alia considered and approved the allotment of 9,00,000 convertible warrants of Rs.10/- each at a price of Rs.169.83, aggregating to Rs.15,28,47,000/- on preferential basis to the persons belonging to Promoter Category.
25-Oct-2024	31-Oct-2024	Half Yearly Results	Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2024 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 We inform you that the Board of Directors of the Company will meet on Thursday 31-October-2024 to consider and approve inter alia the unaudited standalone and consolidated financial results of the Company for the half year ended 30-September-2024.
24-Sep-2024	30-Sep-2024	Stock Split	Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/09/2024 inter alia to consider and approve 1) the proposal for sub-division / split of eqiuty shares of the Company; 2) Alternation in capital clause of the Memorandum of Association of the Company; and 3) seek members approval for the aforesaid items. The Trading WIndow shall be closed upto 48 hours after the declaration of un-audited financial results for half year ended 30-September-2024. The Board of Directors at their meeting held today, 30/Sep/2024 considered and approved sub-division of 1 (one) equity share of Rs.10/- each into 10 (Ten) equity shares of Re.1/- each (Rupee one only), subject to the approval of the shareholders and such other approvals as may be necessary. (As Per BSE Announcement Dated on 30.09.2024)
01-Jul-2024	04-Jul-2024	Raising funds through Debt Instr.	Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/07/2024 inter alia to consider and approve To consider proposal for raising of funds by way of issue of one or more of instruments comprising of equity shares convertible securities of any other description or warrants or debt securities through Private Placement / Preferential Issue / Qualified Institutions Placement or such other methods or combinations thereof and to approve ancillary actions for the above mentioned fund raising subject to such statutory / regulatory approvals as may be necessary.
20-May-2024	27-May-2024	Accounts	Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2024 inter alia to consider and approve Sudarshan Pharma Industries Limited hereby intimates the Stock Exchange about the Board Meeting to be scheduled on 27th May 2024 to discuss and consider the agendas as per the attachment annexed. APPOINTMENT OF MR NILESH THAKKAR , DR VISHVAS JOSHI, DR TAPAS KUMAR NANDI AND MR NIRAV SHAH AT THE BOARD MEETING HELD ON 27.05.2024 (As Per BSE Announcement dated on 27.05.2024)
22-Mar-2024	28-Mar-2024	Others	Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/03/2024 inter alia to consider and approve 1. To give authority to appoint consultants and/or representatives. 2. To avail the credit facility. & to consider and discuss any other matter. Sudarshan Pharma Industries Limited hereby intimates the Stock Exchange about the outcome of the meeting of the Board held on 28th March,2024. (As Per BSE Announcement dated on 28.03.2024)
12-Dec-2023	12-Dec-2023	Change in Other Executives	Sudarshan Pharma Industries Limited hereby intimates the Stock Exchange about the Outcome of the Board Meeting held on December 12, 2023. Agendas discussed in the Board Meeting and the subsequent Outcome are attached in the PDF herewith. Sudarshan Pharma Industries Limited hereby intimates the Stock Exchange about the Outcome of the Board Meeting held on December 12, 2023. Details of the Agendas discussed and the outcome of the Meeting is attached in the PDF herewith. Sudarshan Pharma Industries Limited hereby intimates the Stock Exchange about the Outcome of the Board Meeting held on December 12, 2023. Details of the Agendas discussed along with the Outcome of the Meeting is attached in the PDF herewith. Inter-alia along with other items: 1. Appointment of Mr. Sachin Mehta as the Chief Financial Officer of the Company in addition to being the Joint Managing Director of the Company. 2. Resignation of Mr. Nilesh Thakkar (DIN: 10044097) as an Additional Director in the category of Non-Executive Director. With reference to the captioned subject matter and in compliance with Regulation 30 read with Para A of Part A of Schedule II of the SEBI (LODR) Regulations, 2015, of SEBI (Listing Obligation & Disclosure Requirements) (LODR) Regulations, 2015, This is to inform you that Mr. Nilesh Thakkar, has resigned from the position of Additional Director of the company with effect from 12th December, 2023 due to other commitments and certain other pre-occupations and as stated in the resignation letter as enclosed herewith pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements), 2015. The formal acceptance of the same was placed in the Board Meeting. 3. To approve related party transaction with the following Companies: (a) Ratna Lifesciences Private Limited. (b) Lifescience Chemical Private Limited (As Per BSE Bulletin Dated on 12/12/2023)
03-Nov-2023	10-Nov-2023	Half Yearly Results	Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 inter alia to consider and approve Sudarshan Pharma Industries Limited hereby intimates the Stock Exchange about the intimation of the Board Meeting to be held on 10th November 2023. Sudarshan Pharma Industries Limited hereby intimates the Stock Exchange about the Un-Audited Standalone and Consolidated financial results for the Half year ended September 30, 2023, along with the Limited Review Report of the Auditors thereon. And also puts forward the outcome of other agendas considered in the meeting held on November 10, 2023 as per attachment . (As Per BSE Announcement dated on 10.11.2023)
12-Aug-2023	18-Aug-2023	Subsidiary Company	Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/08/2023 inter alia to consider and approve To give approval for incorporating a subsidiary company in the name and style of LIFESCIENCES CHEMICAL PRIVATE LIMITED in the state of Gujarat subject to approval of registrar of companies as may be required from time to time. Sudarshan Pharma Industries Limited hereby intimates the Stock Exchange about the outcome of the meeting of the Board held on 18th August,2023 (As Per BSE Announcement dated on 18.08.2023)
27-Jul-2023	02-Aug-2023	Acquisitions	Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2023 inter alia to consider and approve With reference to the captioned subject matter Notice is hereby given that a Meeting of the Board of Directors of the company is scheduled to be held on Wednesday August 02 2023 at 02:00 PM inter-alia to consider and approve the following business: 1. To acquire RATNA LIFESCIENCES PRIVATE LIMITED (herein after referred as a Company) as the Wholly-Owned Subsidiary. 2. To incorporate a Subsidiary Company. & to consider and discuss any other matter. The Board of Directors at its meeting held on 02nd August, 2023 approved the agenda contained in the Outcome. Due to the restrictions on the Characters limit, the outcome of the Board meeting is attached in the PDF Format for your records. (As per BSE Announcement Dated on 02/08/2023)
14-Jul-2023	21-Jul-2023	Quarterly Results	Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/07/2023 inter alia to consider and approve Notice is hereby given that a Meeting of the Board of Directors of the company is scheduled to be held on Friday July 21 2023 at 02:00 PM inter-alia to consider and approve the following business: 1. To recommend Final Dividend to the equity shareholders of the Company for the Financial Year 2022-2023. 2. To approve AGM Notice along with Annual Report 3. To fix up date time and venue for annual general meeting; 4. To fix cut-off date for dispatch of annual report 5. To fix cut-off date for e-voting and to fix e-voting period 6. To fix record date for final dividend 7. Re-appointment of Managing Director of the Company. 8. Re-appointment of Joint Managing Director of the Company. 9. To consider and approve ESOP. 10. Appointment of Additional Director (Independent) 11. Increase in Authorized Share Capital 12. To approve related party transaction The Board of Directors at its Meeting held on July 21, 2023 approved the agendas contained in the outcome. Due to restriction on character limit, the Outcome of the Board meeting is attached in the PDF format for your records. (As Per BSE Announcement dated on 21.07.2023) The Company intends to intimate to the Stock Exchange that with reference to the captioned subject matter, this letter is in continuation to the letter dated SPIL/CS/SE/2023-2024/05 to further inform you certain changes and that a Meeting of Board of Directors of the company was held on July 21, 2023 (As per BSE Announcement Dated on 26/07/2023)
20-May-2023	26-May-2023	Accounts	Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2023 inter alia to consider and approve 1. the Audited Standalone & Consolidated financial results for the Half-year & Year ended March 31 2023 2. to recommend Final Dividend to the equity shareholders of the Company for the Financial Year 2022-2023. & to consider and discuss any other matter. The Board of Directors at its Meeting held on May 26, 2023 had discussed and approved the following: 1. Audited Standalone and Consolidated financial results for the Half year and Year ended March 31, 2023, with the auditors' report. 2. Recommend final dividend for the year ended March 31, 2023- it was unanimously decided that this agenda shall be taken and resolved upon at a future date. 3. Approval of related party transactions subject to approval of the members. 4. The appointment of M/s Uttam Nahar & CO., Chartered Accountants, Mumbai, as an Internal Auditor for the FY 2023-2024. 5. The appointment of M/s Vishal N. Manseta, Practicing Company Secretaries, Mumbai as Secretarial Auditor of the Company for the FY 2022-2023. 6. Increase in remuneration of Mr. Hemal Mehta, the Managing Director of the Company subject to approval of members. 7. Increase in remuneration of Mr. Sachin Mehta, the Joint Managing Director of the Company subject to approval of the members. The Board of Directors at its Meeting held on May 26, 2023 had discussed and approved the following inter-alia along with other items: 1. Audited Standalone and Consolidated financial results for the Half year and Year ended March 31, 2023, together with the auditors' report thereon. The Board of Directors at its Meeting held on May 26, 2023 had discussed and approved the following: 1. Audited Standalone and Consolidated financial results for the Half year and Year ended March 31, 2023, with the auditors' report thereon. 2. Recommend final dividend for the year ended March 31, 2023- it was unanimously decided that this agenda shall be taken and resolved upon at a future date. 3. Approval of related party transactions subject to approval of the members . 4. The appointment of M/s Uttam Nahar & CO., Chartered Accountants, Mumbai, as an Internal Auditor for the FY 2023-2024. 5. The appointment of M/s Vishal N. Manseta, Practicing Company Secretaries, Mumbai as Secretarial Auditor of the Company for the FY 2022-2023. 6. Increase in remuneration of Mr. Hemal Mehta, the Managing Director of the Company subject to approval of the members . 7. Increase in remuneration of Mr. Sachin Mehta, the Joint Managing Director of the Company subject to approval of the members . (As Per BSE Announcement Dated on 26.05.2023)

LOGIN HERE

Sudarshan Pharma Industries Ltd

Board Meeting